Trial vaccine could protect against HIV for more than five years
Four days on, three days off HIV treatment as effective as continuous therapy, French study finds
ADVANCE trial shows dolutegravir is highly effective in South Africa
Three forms of PrEP stigma in Kenya
PrEP implant could last well over a year
WHO endorses event-driven PrEP for gay men
South Africa saves $326 million on dolutegravir
Men accounted for two-thirds of HIV transmission in PopART prevention trial
Dolutegravir leads to weight gain in two African studies
